Press Release

Supporting Global Intellectual Property Priorities

PhRMA February 17, 2009

Washington, D.C. (February 17, 2009) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Billy Tauzin issued the following statement regarding PhRMA’s 2009 Special 301 submission (read the report), which outlines global intellectual property priorities:

“The Special 301 process is an important part of the Administration’s efforts to strengthen intellectual property laws and enforcement around the world. Intellectual property protection is vital to creating the incentives essential to spurring the research and development of new medicines. PhRMA and its members appreciate efforts to help patients access new medicines that improve health outcomes.

“PhRMA’s Special 301 submission identifies specific countries that need to improve intellectual property protection and enforcement for pharmaceutical products or that maintain market access barriers which subvert intellectual property protection. Our submission emphasizes counterfeiting problems that present public health concerns both in the United States and around the world. The increasing prevalence of counterfeit medicines demands an aggressive, coordinated response among all U.S. trading partners.

“In addition to seeking improvements in global IP protection, our submission addresses other market access barriers to innovative medicines. These foreign market access barriers have the long-term impact of harming American citizens by costing American jobs and undermining sustainable innovation.

“America’s pharmaceutical research companies are a cornerstone of our high-tech business sector and one of the most significant knowledge-intensive enterprises in the U.S. economy. PhRMA member companies’ research and development efforts contribute dramatically to the health of the U.S. economy but depend on continued innovation and market access for increased growth.

“A worldwide respect for intellectual property is necessary in order to transfer new innovations and discoveries into products we can all use. When other countries fail to protect innovation, it affects the lives of not only Americans but ultimately patients around the globe. Patients around the world are waiting for the more than 2,000 new medicines currently in development by PhRMA member companies."

Click here to read the report.

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives. PhRMA companies are leading the way in the search for new cures. PhRMA members alone invested an estimated $44.5 billion in 2007 in discovering and developing new medicines. Industry-wide research and investment reached a record $58.8 billion in 2007.

PhRMA Internet Address:

For information on stories of hope and survival, visit:

PhRMA en Español:

For information on how innovative medicines save lives, visit:

For information on the Partnership for Prescription Assistance, visit:

For information on the danger of imported drugs, visit: